New Haven, Connecticut 06519


Purpose:

We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments.


Criteria:

Inclusion Criteria: - DSM-IV diagnosis of bipolar disorder - Presence of a current major depressive episode on the SCID - Score of 17 or greater on the HDRS - Failure to respond to two previous medication trials - Capable of giving voluntary written consent Exclusion Criteria: - Hypersensitivity to penicillin or cephalosporin, resulting in anaphylaxis - Significant current substance dependence/abuse within 3 months preceding the trial - Significant history of intravenous drug abuse - Active suicidal ideation - Pregnant/lactating mothers - Significant medical history - Patients on anticoagulation treatment - Patients who test positive for HIV or Hep B or C


NCT ID:

NCT00566111


Primary Contact:

Principal Investigator
Zubin Bhagwagar, MD PhD
Yale University

Kathleen Maloney, BA
Phone: 203-974-7496
Email: kathleen.maloney@yale.edu


Backup Contact:

N/A


Location Contact:

New Haven, Connecticut 06519
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.